Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $0.072
Latest analyst grade actions
1225 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-27
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 43.43 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 43.55 | Oscillator | Neutral |
| Williams %R (14) | -69.04 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.00 (Hist 0.00) | Oscillator | Buy |
| Average Directional Index (14) | 42.84 (+DI 13.1 / -DI 43.3) | Trend | Strong Sell |
| EMA 20 | 0.07 | MA | Strong Sell |
| SMA 20 | 0.07 | MA | Sell |
| EMA 50 | 0.08 | MA | Strong Sell |
| SMA 50 | 0.08 | MA | Strong Sell |
| SMA 200 | 0.10 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
TTM vs. 5-year historical average (annual ratios)
| Metric | AVCNF | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -3.1x | -4.8x · sector 20.8x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 2.7x | -53.2x | Discount |
| Price / Sales | 0.5x | 3.9x | Discount |
| EV / EBITDA | -4.4x | -6.6x | Discount |
| Return on equity | -108.4% | — | Weak |
| Gross margin | 51.9% | 51.0% | In line |
| Debt / Equity | 0.04 | -4.58 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -4.88 | Distress |
Discounted cash flow model
Stock news · updated daily
TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces that in the US, the Company will transition to OTCQB effective October 16, 2026.
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc. and Avicanna Inc. will be presenting live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 17, 2026 | -0.03 | -0.01 | Beat 82.1% | $3.97M |
| May 13, 2026 | -0.03 | -0.00 | Beat 89.0% | $4.80M |
| Nov 17, 2025 | -0.02 | -0.01 | Beat 61.6% | $4.59M |
| Aug 14, 2025 | -0.03 | -0.00 | Beat 85.1% | $4.52M |
| May 14, 2025 | -0.04 | 0.00 | Beat 101.2% | $4.44M |
| Nov 13, 2024 | -0.03 | -0.01 | Beat 81.8% | $4.62M |
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
